Chemotherapy Induced Peripheral Neuropathy Treatment Market Projected at $2.5 Billion by 2029 | Strategic Insights and Forecast Data
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Changed, over the years?
In recent times, the market for treatment of chemotherapy-induced peripheral neuropathy has seen significant expansion. It is projected to rise from $1.66 billion in 2024 to $1.78 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.1%. Factors such as progress in chemotherapy techniques, widening of cancer treatment coverage, scarcity of alternative treatment methods, rising occurrences of cancer, and advancements in neurological research have contributed to the growth during the historical period.
How Much Will the Chemotherapy Induced Peripheral Neuropathy Treatment Market Be Worth in 2029?
The market for treatment of chemotherapy induced peripheral neuropathy is predicted to witness substantial growth in the coming years, reaching a value of $2.5 billion by 2029 with a compound annual growth rate (CAGR) of 8.9%. This anticipated growth during the forecast period is linked to the development of targeted therapies, neuroprotective agents, integrated care pathways, patient-oriented care models, and regulatory support. Key trends throughout the forecast period encompass innovative drug formulations, non-medicinal interventions, therapies based on neuroplasticity, support for long-term survivors, and cognitive behavioral therapies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11967&type=smp
Which is the Largest Company in the Chemotherapy Induced Peripheral Neuropathy Treatment Market?
Major companies operating in the chemotherapy induced peripheral neuropathy treatment market include Hoffmann-La Roche Ltd., Midatech Pharma PLC, Novartis AG, Lee’s Pharmaceutical Holdings Limited, RELIEF THERAPEUTICS Holding SA, Eurofins Advinus, WEX Pharmaceuticals Inc., Asahi Kasei Corporation, MediciNova Inc., Solasia Pharma K.K., ESTEVE, ChromaDex Inc., Apollo Endosurgery Inc., REGENACY PHARMACEUTICALS INC., Novaremed AG, MAKScientific LLC, Sova Pharmaceuticals Inc., Kineta Inc., Aptinyx Inc., Apexian Pharmaceuticals Inc., WinSanTor Inc., Alexion Pharmaceuticals Inc., Sanofi, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Abbott Laboratories, Acorda Therapeutics Inc., Galena Biopharma Inc., Incyte Corporation
What Are the Main Market Drivers in the Chemotherapy Induced Peripheral Neuropathy Treatment Industry?
The growth of the chemotherapy-induced peripheral neuropathy treatment market is anticipated to be driven by the rising occurrence of cancer. Abnormal cell growth and dissemination in the body characterize this disease. Certain chemotherapy drugs used to treat cancer can potentially cause chemotherapy-induced peripheral neuropathy as a side effect. With an upsurge in global cancer incidences, the market for this treatment is expected to expand. For example, in January 2023, the American Cancer Society, a US-based voluntary health organization committed to eradicating cancer, reported that the number of new liver cancer cases in females in the United States rose from 12,660 in 2022 to 13,230 in 2023. Therefore, the escalating prevalence of cancer is fuelling the expansion of the chemotherapy-induced peripheral neuropathy treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=11967&type=smp
How Is the Chemotherapy Induced Peripheral Neuropathy Treatment Market Segments Structured?
The chemotherapy induced peripheral neuropathy treatment market covered in this report is segmented –
1) By Drug Class: Nerve Protective Therapy, Anti-Inflammatory Therapy, Neurotransmitter Based Therapy, Antioxidant, Other Drug Classes
2) By Treatment: Medication, Therapy, Other Treatments
3) By Drug Type: Branded, Generic
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End-User: Hospitals, Research Institutes, Specialty Clinics
Subsegments:
1) By Nerve Protective Therapy: Vitamin B Complex, Alpha-Lipoic Acid, Acetyl-L-Carnitine
2) By Anti-Inflammatory Therapy: Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
3) By Neurotransmitter Based Therapy: Gabapentin, Pregabalin, Duloxetine
4) By Antioxidant: N-acetylcysteine, Glutathione, Coenzyme Q10
5) By Other Drug Classes: Topical Treatments, Opioids, Herbal Remedies
What Strategic Trends Are Transforming the Chemotherapy Induced Peripheral Neuropathy Treatment Market?
The trend of product innovation is increasingly becoming popular in the market for chemotherapy-induced peripheral neuropathy treatment. The established companies in this medical realm are focusing on the introduction of novel products to enhance research capabilities and retain their standing in the market. For example, AlgoTx, a company in the clinical-stage that specifically deals with complicated pain management unveiled the approval of Investigational New Drug Application (IND), for ATX01, its phase 2 trailblazer candidate by the FDA in March 2023. This new treatment option is designed for patients suffering from erythromelalgia. Concurrently, the initial patients in the ATX01 for the Pain of Chemotherapy (ACT) research study targeting chemotherapy-induced peripheral neuropathy (CIPN) have been chosen randomly. The FDA has awarded both initiatives with a fast-track designation.
Access The Full Report Here:
Which Global Regions Offer the Highest Growth in the Chemotherapy Induced Peripheral Neuropathy Treatment Market?
North America was the largest region in the chemotherapy induced peripheral neuropathy treatment market in 2024. Asia-Pacific and Europe are expected to be the fastest-growing regions in the forecast period. The regions covered in the chemotherapy induced peripheral neuropathy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11967
This Report Delivers Insight On:
1. How big is the chemotherapy induced peripheral neuropathy treatment market, and how is it changing globally?
2. Who are the major companies in the chemotherapy induced peripheral neuropathy treatment market, and how are they performing?
3. What are the key opportunities and risks in the chemotherapy induced peripheral neuropathy treatment market right now?
4. Which products or customer segments are growing the most in the chemotherapy induced peripheral neuropathy treatment market?
5. What factors are helping or slowing down the growth of the chemotherapy induced peripheral neuropathy treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
